Tag: notice

Oslo, 19 June 2025

LUXEMBOURG, June 18, 2025 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) (“Tenaris”, or the “Company”) announced today that the Company’s controlling shareholder, San Faustin S.A. (“San Faustin”), has notified the Company that, as a result of Tenaris’s open market repurchases of own shares under its share buyback program publicly announced on May 27, 2025, San Faustin has passively crossed a voting rights threshold triggering a notice requirement under the Luxembourg Transparency Law.

MONTREAL, June 18, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is undertaking a rights offering (the “Rights Offering”). The Company will be offering a maximum of 353,409,888 rights (the “Rights”) to holders (the “Shareholders”) of its common shares (the “Shares”) as at the close of business on the record date of June 25, 2025 (the “Record Date”) on the basis of one (1) Right for each one (1) Share held. Each one (1) Right will entitle the holder to subscribe for one Share (each, a “Rights Share”) at the subscription price of $0.0825 per Rights Share.

MONTRÉAL, 18 juin 2025 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce qu'elle procédera à un placement de droits (le « placement de droits »). La Société offrira un maximum de 353 409 888 droits (les « droits ») aux porteurs (les « actionnaires ») de ses actions ordinaires (les « actions ») inscrits à la fermeture des bureaux le 25 juin 2025 (la « date de référence »), à raison d'un (1) droit pour chaque action détenue. Chaque droit confère au porteur le droit de souscrire à une action (les « droits de souscription d’une action ordinaire », collectivement les « droits de souscription d’actions ordinaires ») au prix de souscription de 0,0825 $ par droit de souscription d’une action ordinaire.

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing is pleased to announce an offering of a non-brokered private placement (the “Offering”) of up to 6,000,000 common shares of the Company (the “Common Shares”) at a price of C$0.10 per Common Share for gross proceeds of up to C$600,000. No finder’s fees or commissions will be payable in connection with the Offering.

WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates on its reorganizational phase.